Esophageal Cancer (Esophageal Adenocarcinoma & Squamous Cell Carcinoma)

Overview

Esophageal cancer is the thirteenth most common cancer and the seventh leading cause of cancer death worldwide, responsible for roughly 500,000 deaths each year, with population-based 5-year survival that has improved over recent decades but still rarely exceeds 20% (Xie et al., New England Journal of Medicine, 2026). Its two main histologic subtypes are biologically distinct diseases that happen to share an organ (Smyth et al., Nature Reviews Disease Primers, 2017). Esophageal squamous cell carcinoma, which arises in the squamous lining of the upper and middle esophagus, accounts for about 85% of cases globally and is concentrated in Eastern Asia and parts of Africa, driven by tobacco, alcohol, hot-beverage consumption, and dietary factors (Morgan et al., Gastroenterology, 2022; Zhong et al., Nature Communications, 2026). Esophageal adenocarcinoma, which arises in glandular (columnar) tissue of the lower esophagus and gastroesophageal junction, is the subtype tied to reflux disease — and it is the one that dominates a Western foregut practice (Xie et al., New England Journal of Medicine, 2026).

The reason EAC belongs at the far end of a reflux cluster is a clear, stepwise biology. Chronic gastroesophageal reflux disease (GERD) is the principal causal risk factor for EAC, and long-standing erosive reflux can produce Barrett's esophagus — the replacement of normal squamous lining with intestinal-type columnar epithelium, and the only known precursor lesion for EAC (Thrift, Nature Reviews Gastroenterology & Hepatology, 2021; Wani et al., AGA Clinical Practice Guideline, 2025). Barrett's esophagus then progresses probabilistically through low-grade dysplasia (LGD) to high-grade dysplasia (HGD) to invasive adenocarcinoma (Fitzgerald, New England Journal of Medicine, 2026). This continuum directly links our GERD / Acid Reflux pillar, Erosive Esophagitis, and Barrett's Esophagus pages to this one, and it is why reflux complications such as a peptic stricture or a manometric EGJOO pattern must always be worked up to exclude an underlying malignancy (see our Esophageal Stricture and EGJOO pages).

The epidemiology explains the urgency. In the United States, EAC incidence rose roughly 5-fold from the 1970s to the 2010s and surpassed ESCC in the late 1990s to become the predominant subtype, a trend attributed largely to rising obesity and GERD (Wani et al., AGA Clinical Practice Guideline, 2025; Xie et al., Scientific Reports, 2025). EAC shows a striking male predominance, with a male-to-female incidence ratio of 6:1 in general and up to 9:1 in the United States, and it is most common in older, overweight white men with reflux symptoms (Xie et al., New England Journal of Medicine, 2026; Rubenstein and Shaheen, Gastroenterology, 2015).

‍

Causes

Esophageal cancer is caused by the accumulation of genetic and cellular damage in the esophageal lining in response to chronic injury, with the inciting injury differing sharply by subtype (Smyth et al., Nature Reviews Disease Primers, 2017):

• Chronic acid and bile reflux (the cause of most adenocarcinoma). Repeated reflux injures the esophageal epithelium, triggering inflammation and the metaplasia–dysplasia–carcinoma sequence that leads through Barrett's esophagus to EAC (Thrift, Nature Reviews Gastroenterology & Hepatology, 2021). The risk rises steeply with the frequency, severity, and duration of reflux symptoms — individuals with recurrent, long-standing (>20 years) symptoms have had up to a roughly 44-fold higher risk of EAC compared with those with infrequent symptoms (Thrift, Nature Reviews Gastroenterology & Hepatology, 2021).

• Barrett's esophagus (the precursor lesion). EAC arises almost exclusively from Barrett's metaplasia or from intestinalized metaplastic cells at the gastric cardia; Barrett's is the only identifiable precursor (Wani et al., AGA Clinical Practice Guideline, 2025). See our Barrett's Esophagus page.

• Tobacco and alcohol (the main drivers of squamous cell carcinoma). Heavy smoking and alcohol use, along with hot-beverage consumption and diets low in fruits and vegetables, are the dominant risk factors for ESCC (Zhong et al., Nature Communications, 2026). Smoking also modestly increases EAC risk, but alcohol is not a significant EAC risk factor (Ebell, American Family Physician, 2025).

• Obesity, especially visceral adiposity. A higher body-mass index is associated with graded increases in EAC risk, mediated both through reflux and through reflux-independent mechanisms such as systemic inflammation and metabolic change (Xie et al., New England Journal of Medicine, 2026).

‍

Risk Factors

• Chronic GERD, particularly erosive reflux disease — the leading risk factor for EAC; the association is strongest with erosive esophagitis rather than nonerosive reflux (Xie et al., New England Journal of Medicine, 2026). See our Erosive Esophagitis and GERD / Acid Reflux pages.

• Barrett's esophagus (and the grade/length of dysplasia) — longer segments and higher-grade dysplasia carry greater progression risk (Wani et al., AGA Clinical Practice Guideline, 2025).

• Male sex, older age, and white race — EAC is markedly more common in older white men (Rubenstein and Shaheen, Gastroenterology, 2015).

• Obesity / central adiposity — a major, graded EAC risk factor (Xie et al., New England Journal of Medicine, 2026).

• Tobacco smoking — a risk factor for both subtypes, and a driver of Barrett's progression (Wani et al., AGA Clinical Practice Guideline, 2025).

• Heavy alcohol use — a major, specific risk factor for ESCC (Zhong et al., Nature Communications, 2026).

• Family history of Barrett's esophagus or EAC — a high-risk feature used in screening criteria (NCCN, Esophageal and EGJ Cancers, 2026).

• For ESCC specifically — Achalasia, prior caustic (lye) injury, prior head and neck cancer, and tylosis also raise risk (NCCN, Esophageal and EGJ Cancers, 2026). This is one reason long-standing achalasia warrants specialist follow-up.

‍

How Esophageal Cancer Affects the Body

The esophagus is a muscular, distensible tube, so an enlarging tumor can grow for a long time before it produces symptoms — which is why warning signs typically appear only when the cancer is locally advanced or metastatic (Smyth et al., Nature Reviews Disease Primers, 2017). As the tumor encroaches on the lumen, it mechanically obstructs the passage of food, producing the hallmark progressive dysphagia that begins with solids and advances to soft foods and liquids (Lagergren et al., Lancet, 2017). Reduced intake and the metabolic demands of the tumor drive involuntary weight loss and malnutrition, and chronic occult bleeding can cause anemia and fatigue (Smyth et al., Nature Reviews Disease Primers, 2017). Local extension can involve the recurrent laryngeal nerve (causing hoarseness) or the airway (causing cough or aspiration), and the tumor spreads to regional lymph nodes and then to distant organs such as the liver (Smyth et al., Nature Reviews Disease Primers, 2017). Because the depth of invasion into the esophageal wall closely tracks the risk of lymph-node spread, the biology is stage-defining: intramucosal (T1a) tumors have a low rate of nodal metastasis and can often be cured endoscopically, whereas submucosal (T1b) invasion is associated with lymph-node metastasis in roughly 23% of cases (Xie et al., New England Journal of Medicine, 2026).

‍

Complications

• Malignant dysphagia and obstruction — progressive inability to swallow, leading to dehydration and malnutrition (Lagergren et al., Lancet, 2017).

• Weight loss, cachexia, and anemia — from reduced intake, tumor metabolism, and chronic bleeding (Smyth et al., Nature Reviews Disease Primers, 2017).

• Aspiration pneumonia — from obstruction, regurgitation, or airway involvement (Torpy et al., JAMA, 2010).

• Tracheoesophageal fistula and hemorrhage — from local tumor invasion in advanced disease.

• Metastatic disease — most commonly to regional nodes, liver, lung, and bone; roughly 40% of U.S. patients are diagnosed with distant-stage disease (Thrift, Digestive Diseases and Sciences, 2018).

• Treatment-related morbidity — esophagectomy carries real risks (anastomotic leak, pulmonary complications, long-term dysphagia and reflux), which is precisely why organ-sparing endoscopic therapy is favored for the earliest-stage disease (Naveed and Kubiliun, Current Oncology Reports, 2018).

‍

Symptoms & Signs

• Progressive dysphagia — the most common presenting symptom, typically beginning with solids and worsening over weeks to months (Rubenstein and Shaheen, Gastroenterology, 2015).

• Unintentional weight loss — a frequent and ominous accompanying sign (Lagergren et al., Lancet, 2017).

• Odynophagia (painful swallowing) and chest or epigastric pain (Cai et al., Cochrane Database of Systematic Reviews, 2025).

• New-onset or worsening dyspepsia/heartburn, or a change in long-standing reflux symptoms (Cai et al., Cochrane Database of Systematic Reviews, 2025).

• Hoarseness or chronic cough — may signal recurrent laryngeal nerve involvement or aspiration (Smyth et al., Nature Reviews Disease Primers, 2017).

• Anemia, fatigue, hematemesis, or melena — from chronic or overt gastrointestinal bleeding (Smyth et al., Nature Reviews Disease Primers, 2017).

A critical caveat: symptoms generally appear late, and almost half of patients with EAC report no troublesome reflux symptoms at all, which limits the reach of symptom-based detection and underscores the value of recognizing at-risk patients early (Xie et al., New England Journal of Medicine, 2026).

‍

Diagnosis

• Upper endoscopy (EGD) with biopsy — the gold standard. Endoscopy directly visualizes the tumor and allows biopsy for histologic confirmation; a minimum of six to eight biopsies is recommended for adequate tissue (Smyth et al., Nature Reviews Disease Primers, 2017; NCCN, Esophageal and EGJ Cancers, 2026). The tumor's location relative to the teeth and the EGJ, its length, circumferential extent, and degree of obstruction are documented, along with any Barrett's esophagus characterized by the Prague criteria (NCCN, Esophageal and EGJ Cancers, 2026).

• Endoscopic resection (ER) for accurate early staging. For superficial lesions (Tis, T1a, or T1b), ER (EMR or ESD) provides the most accurate assessment of depth of invasion and is often both diagnostic and therapeutic (NCCN, Esophageal and EGJ Cancers, 2026; Xie et al., New England Journal of Medicine, 2026).

• Staging with cross-sectional and functional imaging. Chest/abdomen CT with contrast and FDG-PET/CT (if no M1 disease) assess for distant metastases, and endoscopic ultrasound (EUS) defines depth of invasion (T) and nodal status (N) when there is no metastatic disease (NCCN, Esophageal and EGJ Cancers, 2026).

• Biomarker testing (for advanced/metastatic adenocarcinoma). NCCN recommends universal testing for microsatellite instability (MSI)/mismatch-repair (MMR) status and PD-L1 in all newly diagnosed patients, with HER2 (ERBB2) and CLDN18.2 testing when advanced/metastatic adenocarcinoma is documented or suspected (NCCN, Esophageal and EGJ Cancers, 2026).

• Staging system. Esophageal cancer is staged by the AJCC TNM system, with separate prognostic stage groupings for adenocarcinoma and squamous cell carcinoma and distinct clinical (cTNM), pathologic (pTNM), and post-neoadjuvant (ypTNM) classifications (NCCN, Esophageal and EGJ Cancers, 2026).

‍

Differential Diagnosis

• Benign peptic (reflux) stricture or Schatzki ring — the most important benign mimic of malignant dysphagia; distinguished by biopsy (see our Esophageal Stricture page) (Smyth et al., Nature Reviews Disease Primers, 2017).

• Achalasia and other motility disorders / EGJOO — functional obstruction that can mimic a malignant stricture; notably, a subtype of achalasia ("pseudoachalasia") can be caused by an infiltrating cancer at the EGJ (see our Achalasia and EGJOO pages).

• Eosinophilic esophagitis — a cause of dysphagia and food impaction, especially in younger patients; diagnosed by biopsy.

• Barrett's esophagus with dysplasia (without invasive cancer) — the precursor state, distinguished by histology (see our Barrett's Esophagus page) (Fitzgerald, New England Journal of Medicine, 2026).

• Gastric cancer of the cardia extending into the EGJ — classified by Siewert category (see our Gastric Cancer page) (NCCN, Esophageal and EGJ Cancers, 2026).

• Esophageal web, infectious or pill esophagitis, and extrinsic compression (Smyth et al., Nature Reviews Disease Primers, 2017).

‍

Lifestyle Modifications

Lifestyle measures matter most for risk reduction and prevention along the reflux pathway, and for optimizing a patient's condition before and during treatment:

• Smoking cessation and limiting alcohol — reduce risk of both subtypes and are integrated into oncologic care (NCCN, Esophageal and EGJ Cancers, 2026).

• Weight management — given the strong obesity–EAC link; notably, a meta-analysis of 14 cohort studies found a 31% decreased risk of EAC after bariatric surgery, suggesting weight loss may counteract the disease in people with obesity (Xie et al., New England Journal of Medicine, 2026). This is a direct link to our bariatric surgery pages.

• Reflux control — adherence to anti-reflux measures and acid suppression for GERD and Barrett's, recognizing that while these improve symptoms and are standard in Barrett's, the evidence that antireflux treatment itself prevents EAC is inconsistent (Xie et al., New England Journal of Medicine, 2026; Maret-Ouda et al., JAMA, 2020). See our GERD / Acid Reflux pillar.

• Nutritional optimization — nutritional assessment and counseling are a formal part of the workup, because malnutrition is common and affects treatment tolerance (NCCN, Esophageal and EGJ Cancers, 2026).

‍

Treatment Options

Treatment is entirely stage- and fitness-dependent, decided in a multidisciplinary setting, and the single most important principle is that early, localized disease is potentially curable — increasingly without removing the esophagus — whereas locally advanced disease requires multimodal therapy (NCCN, Esophageal and EGJ Cancers, 2026). The following reflects the NCCN approach for adenocarcinoma (the reflux-related subtype); all recommendations are category 2A unless otherwise noted.

• High-grade dysplasia (Tis) and intramucosal cancer (T1a). Endoscopic therapy — endoscopic resection with or without ablation — is the preferred treatment, because the risk of lymph-node metastasis is low; esophagectomy is an alternative, particularly for extensive or nodular disease not controlled endoscopically (NCCN, Esophageal and EGJ Cancers, 2026; Xie et al., New England Journal of Medicine, 2026). Endoscopic resection has replaced esophagectomy as the treatment of choice for T1a cancer without nodal disease (Xie et al., New England Journal of Medicine, 2026).

• Superficial submucosal cancer (superficial T1b). Endoscopic resection with or without ablation, or esophagectomy, are both options; the choice weighs low-risk versus high-risk pathologic features (size ≤2 cm, differentiation, absence of LVI, depth ≤500 μm define low risk) against the morbidity of surgery (NCCN, Esophageal and EGJ Cancers, 2026).

• Deeper T1b (N0) and T1b–T2 N0 low-risk lesions. Esophagectomy is the standard; because T1b tumors carry roughly a 23% rate of nodal metastasis, overall survival is generally better with esophagectomy than endoscopic therapy, though endoscopic treatment remains an option in selected or non-surgical patients (Xie et al., New England Journal of Medicine, 2026; NCCN, Esophageal and EGJ Cancers, 2026).

• Locally advanced, resectable disease (high-risk cT2, node-positive, or cT3–cT4a). Perioperative systemic therapy (category 1) is preferred, with preoperative chemoradiation as an alternative; neoadjuvant or perioperative immune checkpoint inhibitor therapy should be considered if the tumor is MSI-high/mismatch-repair deficient (NCCN, Esophageal and EGJ Cancers, 2026). Definitive chemoradiation is reserved for those who decline surgery.

• Unresectable (cT4b) disease. Definitive chemoradiation, or chemotherapy alone in the setting of invasion of the trachea, great vessels, or heart (NCCN, Esophageal and EGJ Cancers, 2026).

• Non-surgical candidates and metastatic (stage IVB) disease. Options range from definitive chemoradiation (for those able to tolerate it) to palliative radiation, systemic therapy, endoluminal stenting for obstruction, and best supportive care (NCCN, Esophageal and EGJ Cancers, 2026).

• Esophagectomy technique. When surgery is indicated, transhiatal, transthoracic, or minimally invasive esophagectomy with gastric reconstruction is performed, generally with a feeding jejunostomy for nutritional support; minimally invasive approaches achieve good oncologic results with reduced morbidity (NCCN, Esophageal and EGJ Cancers, 2026; Mönig et al., Annals of the New York Academy of Sciences, 2018).

‍

When to See a Doctor

Any new or progressive difficulty swallowing warrants prompt evaluation — dysphagia is never a normal symptom and always requires explanation, and in esophageal cancer it is often the first sign of established disease (Smyth et al., Nature Reviews Disease Primers, 2017). Evaluation is especially important for a patient with long-standing reflux who develops new dysphagia, a change in reflux symptoms, or unexplained weight loss. Patients with chronic GERD and additional risk factors (male sex, age >50, white race, obesity, smoking, or a family history of Barrett's/EAC) should discuss screening endoscopy for Barrett's esophagus with a specialist, as recommended by several GI societies (NCCN, Esophageal and EGJ Cancers, 2026).

‍

When to Seek Treatment

Seek prompt specialized evaluation for the alarm features that point toward malignancy: progressive dysphagia, significant unintentional weight loss, odynophagia, anemia, or gastrointestinal bleeding (vomiting blood or black/tarry stools) (Rubenstein and Shaheen, Gastroenterology, 2015; Smyth et al., Nature Reviews Disease Primers, 2017). A food bolus impaction, or the inability to swallow saliva, requires urgent care. Because the prognosis of esophageal cancer is so strongly tied to stage at diagnosis, the interval between the onset of alarm symptoms and endoscopic evaluation genuinely matters — delays allow the window for curative, organ-sparing treatment to close (Thrift, Digestive Diseases and Sciences, 2018).

‍

Long-Term Outlook

The long-term outlook hinges on early detection. Survival has improved meaningfully over recent decades — driven by earlier detection through Barrett's surveillance, better patient selection, improved surgical and perioperative care, and the addition of neoadjuvant therapy (Coleman et al., Gastroenterology, 2018). For patients treated at an early stage, long-term survival is excellent and organ preservation is often possible, but it requires lifelong endoscopic surveillance after endoscopic eradication therapy — EGD every 3 months in the first year, every 6 months in the second year, then annually indefinitely for Tis/T1a disease — because metachronous lesions and residual Barrett's can recur (NCCN, Esophageal and EGJ Cancers, 2026). For patients with a reflux and Barrett's history, the long-term strategy is proactive: control the reflux, undergo appropriate Barrett's surveillance and eradication therapy for dysplasia, and treat any neoplasia at its earliest, most curable point (Wani et al., AGA Clinical Practice Guideline, 2025). That is the entire argument for taking reflux seriously years before cancer is ever a consideration (see our GERD / Acid Reflux and Barrett's Esophagus pages).

‍

Prognosis

The overall prognosis for esophageal cancer remains poor, driven by late presentation, with population-based 5-year survival rarely exceeding 20% (Xie et al., New England Journal of Medicine, 2026). But that headline number masks the dominant truth of this disease: survival is profoundly stage-dependent. In U.S. SEER data, 5-year survival is roughly 46.7% for localized disease, 25.1% for regional disease, and only 4.8% for distant disease (Cai et al., Cochrane Database of Systematic Reviews, 2025). Stage-specific EAC survival in a contemporary cohort was approximately 80% for stage I, 57% for stage II, 39% for stage III, and under 10% for stage IV (Sawas et al., Clinical Gastroenterology and Hepatology, 2020). For the earliest, endoscopically treated disease (HGD and intramucosal cancer), cure rates approach those of esophagectomy with far less morbidity (Naveed and Kubiliun, Current Oncology Reports, 2018). The strongest prognostic factor is tumor stage — particularly pathologic stage and response to neoadjuvant therapy — along with performance status and comorbidity (Coleman et al., Gastroenterology, 2018). The sobering counterpoint is that about 40% of U.S. patients are still diagnosed with distant-stage disease (Thrift, Digestive Diseases and Sciences, 2018).

Why Choose Dr. de la Cruz‑Muñoz

Esophageal cancer is the reason reflux disease is never "just heartburn." It sits at the end of a continuum that begins with acid reflux, passes through erosive esophagitis and Barrett's esophagus, and — in a minority of patients — ends in adenocarcinoma, which is precisely why it should be managed by a foregut surgeon who understands and treats that entire continuum. Dr. Nestor de la Cruz-Muñoz, MD, FACS, DABOM, is a board-certified minimally invasive foregut and bariatric surgeon in Miami whose practice is built around the esophagus and the gastroesophageal junction — from reflux and hiatal hernia, to Barrett's surveillance and eradication therapy, to the surgical treatment of esophageal and EGJ cancer. For patients with reflux and Barrett's, that means a prevention-first philosophy: aggressive reflux control, meticulous surveillance, and endoscopic eradication of dysplasia before it ever becomes invasive cancer. For patients who present with a suspicious stricture or dysphagia, it means malignancy is always excluded before a narrowing is called benign, and early-stage cancers are staged accurately so that the least-destructive curative option — often endoscopic resection rather than esophagectomy — can be offered. And when esophagectomy is required, it is approached with modern, minimally invasive technique and multidisciplinary oncologic coordination. Because obesity is itself a major driver of EAC, this practice is also uniquely positioned to address the metabolic root of the disease (see our bariatric surgery pages). That whole-esophagus, prevention-through-treatment expertise is what makes this practice a trusted destination across South Florida for reflux, Barrett's, and esophageal cancer.

‍